The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended six novel medicines for approval at its ...

The UK’s National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending that ...

Japanese drugmaker Astellas and US pharma giant Pfizer have announced longer-term follow-up results from an open-label ...

Privately-held French drugmaker Servier and China-based BioNova Pharmaceuticals today announce that they have entered into a ...

Among the companies displaying the strength of Chinese research in oncology at the 2025 ASCO Annual Meeting will be Hutchmed.

Welcome to The Pharma Letter ’s real-time coverage of the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, ...

UK pharma major GSK (LSE: GSK) yesterday announced that the US Food and Drug Administration (FDA) has approved Nucala ...

Swiss pharma major Roche (ROG: SIX) has reported updated results from its Phase III STARGLO trial, showing that a ...

The oncology community’s biggest gathering returns to Chicago from May 30 to June 3, and all signs suggest the 2025 ASCO ...

The US Food and Drug Administration (FDA) has approved Roche’s (ROG: SIX) Susvimo (ranibizumab injection) 100mg/mL for the ...

At its May meeting, the European Medicines Agency’s (EMA) human medicines committee (CHMP) adopted positive opinions for three biosimilar medicines: ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) today revealed it has approved Akantior (polihexanide) to treat acanthamoeba keratitis (AK).